What is William Blair’s Forecast for Amgen FY2025 Earnings?

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at William Blair decreased their FY2025 EPS estimates for Amgen in a research report issued to clients and investors on Monday, April 14th. William Blair analyst M. Phipps now anticipates that the medical research company will earn $20.51 per share for the year, down from their previous forecast of $20.55. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

AMGN has been the subject of a number of other research reports. Piper Sandler increased their price target on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Johnson Rice set a $294.00 price target on Amgen in a research note on Wednesday, March 5th. UBS Group raised their price objective on Amgen from $315.00 to $319.00 and gave the company a “neutral” rating in a research note on Monday. Truist Financial decreased their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research report on Wednesday, January 8th. Finally, Bank of America increased their price target on shares of Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a research report on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $314.91.

Amgen Price Performance

Amgen stock opened at $282.64 on Wednesday. The company has a market cap of $151.96 billion, a P/E ratio of 37.44, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. Amgen has a one year low of $253.30 and a one year high of $346.85. The business has a fifty day moving average of $303.78 and a two-hundred day moving average of $294.82. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.37%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s payout ratio is currently 126.09%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David M. Reese sold 25,225 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

Institutional Investors Weigh In On Amgen

Several hedge funds have recently modified their holdings of AMGN. Centricity Wealth Management LLC purchased a new position in Amgen in the 4th quarter valued at about $25,000. Pinney & Scofield Inc. acquired a new position in shares of Amgen in the fourth quarter worth about $26,000. Ritter Daniher Financial Advisory LLC DE boosted its holdings in Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 51 shares during the last quarter. Synergy Investment Management LLC acquired a new stake in Amgen during the 4th quarter valued at approximately $34,000. Finally, Atala Financial Inc purchased a new stake in Amgen during the 4th quarter worth approximately $34,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.